Assessing and Treating ADHD in Adult and Adolescent Patients: Clinical Pearls and Practical Strategies
You need to be logged in to continue. Please Log In or Register using the box at the top right of this page.
Release Date: June 04, 2012
Expiration Date: June 04, 2013
Expected time to complete this activity as designed: 60 minutes
There are no fees for participating in or receiving credit for this online activity.
The agenda of the Assessing and Treating ADHD in Adult and Adolescent Patients: Clinical Pearls and Practical Strategieshas been planned to create a curriculum that provides clinicians with knowledge on the assessment and treatment of adult attention deficit hyperactivity disorder (ADHD) which they can integrate into clinical practice. In this video-based activity, information presentation will occur in two modules; both modules must be viewed to earn credit. In the first module, Dr. Lenard Adler will discuss the diagnosis and management of ADHD from adolescence into adulthood with a brief Q&A session with the moderator, Dr. Anthony Rostain.
In the second module, Dr. Rostain will discuss treatment modalities and again further illustrate key points for the audience through two brief case studies followed by a discussion with Dr. Adler. The second module will also discuss and direct the learner to the related practice support and assessment tools.
This activity is designed for physicians, pharmacists, physician assistants, nurses, and other health care professionals who provide care to adult and adolescent patients with ADHD.
Upon completion of this educational activity, participants should be able to:
- Apply criteria to definitely diagnose ADHD in adult and adolescent patients
- Practice methods of individualized treatment plans incorporating pharmacotherapy and psychotherapeutic modalities
- Develop a strategy for a comprehensive treatment plan that includes monitoring for medication adherence for effective management of ADHD in adult and adolescent patients
Diagnosis and Management of ADHD from Adolescence into Adulthood – Lenard A. Adler, MD
Case Studies in Adolescent and Adult ADHD − Anthony L. Rostain, MD
Instructions for Participation and Credit
This activity is eligible for credit through June 4, 2013. After this date, this activity will expire and no further credit will be awarded.
- Read the target audience, learning objectives, and faculty disclosures.
- You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
- Complete the educational content as designed.
- Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
- Complete the activity evaluation survey to provide feedback and information useful for future programming.
- Certificates may be printed immediately after successfully completing the post-test and activity evaluation.
Lenard A. Adler, MD
Director, Adult ADHD Program
Professor of Psychiatry and
Child and Adolescent Psychiatry
New York University School of Medicine
New York, New York
Dr. Lenard Adler received his medical degree from Emory University School of Medicine, Atlanta, Georgia. He continued his postdoctoral training at New York University (NYU) School of Medicine with an internship in psychiatry/medicine, and a residency/chief residency in psychiatry. He is currently director of the adult ADHD program and a professor of psychiatry and child and adolescent psychiatry at NYU School of Medicine.
Dr. Adler has American Board of Psychiatry and Neurology certification, and is a member of several professional societies including the American Medical Association, the American Psychiatric Association, the Society for Biological Psychiatry, and the National Association for Research in Nervous and Mental Disorders. He is an ad hoc reviewer for the Journal of Clinical Psychiatry, American Journal of Psychiatry, Archives of General Psychiatry, Pediatrics, and the Journal of Child and Adolescent Psychopharmacology, among others. Dr. Adler’s major research interests are designed to establish improved methods of assessment (via clinical rating scales) and novel pharmacotherapies and include adult ADHD – diagnosis, assessment and treatment, and movement disorders – tardive dyskinesia and neuroleptic-induced akathisia.
Anthony L. Rostain, MD
Professor of Psychiatry and Pediatrics
University of Pennsylvania School of Medicine
Director, Adult ADHD Treatment and Research Program
Penn Behavioral Health, University of Pennsylvania Health System
Director, Developmental Neuropsychiatry Program
Behavioral Health Center, The Children’s Hospital of Philadelphia
Dr. Anthony Rostain received his medical degree from the New York School of Medicine, then earned his master’s degree in sociology from the University of Pennsylvania. He completed a residency in pediatrics at Children's Hospital of Philadelphia (CHOP), a residency in adult psychiatry at the Hospital of the University of Pennsylvania, and a fellowship in child and adolescent psychiatry at Philadelphia Child Guidance Center. Dr. Rostain is a professor of both psychiatry and pediatrics at the University of Pennsylvania School of Medicine where he is director of education for the Department of Psychiatry and where he directs the Adult ADHD Treatment and Research Program. Dr. Rostain also directs the Developmental Neuropsychiatry Program at the Behavioral Health Center of CHOP.
Dr. Rostain is certified by the American Board of Pediatrics, the American Board of Psychiatry and Neurology (psychiatry), and the American Board of Psychiatry and Neurology (child and adolescent psychiatry). He is a distinguished fellow of the American Psychiatric Association, the American Academy of Child and Adolescent Psychiatry, and the American Academy of Pediatrics. He is also a member of the executive council of the American Association of Directors of Psychiatry Residency Training (AADPRT) in charge of the Model Curriculum Committee. Dr. Rostain is on the editorial board of Academic Psychiatry and the Journal of Attention Disorders, and is an editorial board member of the American College of Psychiatry PRITE (Psychiatry Residency Inservice Training Examination). He has published numerous peer-reviewed articles, books, chapters and abstracts on ADHD in adults, adolescents, and children.
Accreditation Statement: MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Designation Statement: MediCom Worldwide, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 1.0 contact hour of Continuing Education Credit. Universal Activity Number: 827-0000-12-313-H01-P. Knowledge-based CPE activity.
In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when registering for a CPE program. Please make sure to provide this information in your Member Profile accessed through the Member Center on the home page of this site.
Accreditation Statement: MediCom Worldwide, Inc., 101 Washington Street, Morrisville, PA 19067 is approved by the California Board of Registered Nursing, Provider Number CEP11380. MediCom designates this CNE activity for 1.0 contact hour. Program Number: 12-313-282
As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.
Dr. Lenard Adler has received consultant fees and formal advisory activities from Alcobra Ltd.; Otsuka Pharmaceutical Co., Ltd.; and Shire; as well as consultant fees from Major League Baseball. In addition, he has received grant support related to research activities from Bristol-Myers Squibb; Chelsea Therapeutics; Shire; and the National Institute on Drug Abuse (NIDA). Dr. Adler has also received royalties and licensing fees from NYU School of Medicine and owns significant holdings in Alcobra.
Dr. Anthony Rostain has received consultant fees from Janssen Scientific Affairs, LLC and Shire.
Planning Committee Disclosures
The individuals listed below from MediCom Worldwide, Inc. reported the following for this activity: Joan Meyer, RN, MHA, executive director, has no relevant financial relationships.
Peer Reviewer Disclosure
In accordance with MediCom Worldwide, Inc. policy, all content is reviewed by external independent peer reviewers for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.
Off-Label Disclosures/Investigational Disclosures
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Further, attendees/participants should appraise the information presented critically and are encouraged to consult appropriate resources for any product or device mentioned in this program.
Dr. Adler has indicated that he does intend to discuss off-label uses of drugs, mechanical devices, biologics or diagnostics approved by the US Food and Drug Administration (FDA) for use in the US.
Dr. Rostain has indicated that he does not intend to discuss off-label uses of drugs, mechanical devices, biologics or diagnostics approved by the US Food and Drug Administration (FDA) for use in the US.
Dr. Adler and Dr. Rostain have indicated that they do not intend to discuss investigational drugs, mechanical devices, biologics or diagnostics not approved by the FDA for use in the US.
MediCom Worldwide, Inc. requires Internet Explorer® version 7.0 or higher, or Firefox 3.0 or higher, a computer running Windows® XP, Windows® Vista, Windows® 7, or Mac OS X, 512MB of RAM or greater, 1.5 GHZ or faster processor, and a screen resolution of 1024x768 or higher. Certain educational activities may require additional software to view. These activities will be marked with the information and/or links to the required software. That software may be Adobe® Flash® Player, Adobe® Acrobat®, Windows Media® Player or Microsoft® Silverlight™.
If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at email@example.com.
Provided by MediCom Worldwide, Inc.
This activity is supported by an independent educational grant from Shire plc
©2012 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.
You need to be logged in to continue. Please Log In or Register using the box at the top right of this page.